Zinc histidine - Nobelpharma
Alternative Names: NOBELZIN; NPC-25; ZintusLatest Information Update: 09 Oct 2024
Price :
$50 *
At a glance
- Originator Nobelpharma
- Class Zinc compounds
- Mechanism of Action Zinc replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatolenticular degeneration
- Registered Hypozincaemia
Most Recent Events
- 03 Oct 2024 Nobelpharma intends to appeal to Intellectual Property High Court against Sawai Pharmaceutical in Japan
- 26 Mar 2024 Registered for Hypozincaemia in Japan (PO)
- 25 Jul 2023 Nobelpharma anticipates approval of Zinc histidine for Hypozincaemia in Japan in January 2024 (Nobelpharma pipeline, July 2023)